Health Trials

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

ConditionsAmyloidosisBasal Cell CarcinomaBiliary Tract CarcinomaBladder CarcinomaBreast CarcinomaCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaFallopian Tube CarcinomaGastroesophageal Junction CarcinomaGlioblastomaHead and Neck CarcinomaHematopoietic and Lymphatic System NeoplasmHepatocellular CarcinomaHodgkin LymphomaLung CarcinomaMalignant Solid NeoplasmMantle Cell LymphomaMelanomaMerkel Cell CarcinomaMultiple MyelomaMyelodysplastic SyndromeOvarian CarcinomaPancreatic CarcinomaPrimary Peritoneal CarcinomaProstate CarcinomaRenal Cell CarcinomaSquamous Cell CarcinomaUrothelial Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMayo Clinic

About this trial

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Eligibility criteria

Qualifiers

Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent

Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network [NCCN], American Society of Clinical Oncology [ASCO], American Society of Hematology [ASH], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines

A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program

Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician

Disqualifiers

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.

Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial

Individuals who require continuous (24/7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study

Trial design

Treatments tested in this trial

  • Cancer Therapeutic Procedure
  • Cancer Therapeutic Procedure
  • Questionnaire Administration

Treatment groups

27 Participants
are divided into 1 treatment group

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov